MedTrace Logo

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 218

Last updated 2013-07-02

Study results available
· View outcomes & findings →

Summary

Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

[18F] Flutemetamol

Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.

Sponsors & Collaborators

  • i3 Statprobe

    collaborator INDUSTRY

  • Medpace, Inc.

    collaborator INDUSTRY

  • GE Healthcare

    lead INDUSTRY

Principal Investigators

  • Paul Sherwin, MD, PhD · GE Healthcare

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265394 on ClinicalTrials.gov